Our advisors are a group of leading experts in Neuroscience, Cardiology, Drug Discovery and Development, as well as Drug Delivery and Business.

Advisory Boards

 

Scientific Advisory Board

Helen

Helen M. Burt, PhD, CAHS, OC

Angiotech Professor of drug delivery, UBC Faculty of Pharmaceutical Sciences. Former Director, Research for Angiotech Pharmaceuticals Inc. Expert in development of polymer-based drug delivery systems for controlled and localized drug delivery.

Howard

Howard Feldman, MD, FRCPC

Professor, UCSD, VP & Therapeutic Area Head, Global Clinical Research, Neuroscience, Bristol-Myers Squibb (2009-2011). Led multiple international clinical trials for major pharma companies, e.g. GSK, Pfizer, Lilly, Janssen, Sanofi, Novartis, Boehringer Ingelheim, Bayer and Roche.

John

John Cairns, MD, FRCPC, FRCP (Lond.), FCAHS, FACC

Professor, Medicine, UBC Division of Cardiology. Principal investigator of multiple clinical trials for major pharma companies, e.g. AstraZeneca, Sanofi and Genentech. Chaired Steering Committees of numerous cardiovascular clinical trials.

Business Advisory Board

Malcolm

Malcolm Kendall, MBA

Over 28 yrs. experience in leadership, operations & venture capital. Current co-founder & CEO of Microbiome Insights. Serial entrepreneur. Former investment professional with several Life Science VC firms including MDS Capital (now Lumira Capital) & Intersouth Partners.

Peng

Peng Wang, PhD

Led discovery and development of over 30 new drug candidates in US and China. Among them, Reslizumab, Cinquil™ has been launched globally and Sanbexin™ has been launched in China.

William

William Wei-Guo Jia, MSc, PhD

Company co-founder. Associate Professor, Department of Surgery, UBC. Founder and Chief Scientific Officer of several high-tech companies, including Panagin Pharmaceuticals, Pepmetric Biotech Inc. and ViroGin Biotech.

 

Leadership Team ] [ Advisory Boards ]